Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study
- PMID: 40601887
- DOI: 10.1212/WNL.0000000000213909
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study
Erratum for
-
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.Neurology. 2025 May 13;104(9):e213574. doi: 10.1212/WNL.0000000000213574. Epub 2025 Apr 17. Neurology. 2025. PMID: 40245351 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources